[go: up one dir, main page]

WO2002045723A3 - Inflammatory cytokine secretion inhibition with modified mammalian blood - Google Patents

Inflammatory cytokine secretion inhibition with modified mammalian blood Download PDF

Info

Publication number
WO2002045723A3
WO2002045723A3 PCT/CA2001/001745 CA0101745W WO0245723A3 WO 2002045723 A3 WO2002045723 A3 WO 2002045723A3 CA 0101745 W CA0101745 W CA 0101745W WO 0245723 A3 WO0245723 A3 WO 0245723A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian blood
inflammatory cytokine
cytokine secretion
modified mammalian
secretion inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2001/001745
Other languages
French (fr)
Other versions
WO2002045723A2 (en
WO2002045723A9 (en
Inventor
Anthony Ernest Bolton
Arkady Mandel
Daniel Nathan Sauder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Priority to EP20010999376 priority Critical patent/EP1365842A2/en
Priority to CA002430937A priority patent/CA2430937A1/en
Priority to AU2002215735A priority patent/AU2002215735A1/en
Publication of WO2002045723A2 publication Critical patent/WO2002045723A2/en
Publication of WO2002045723A9 publication Critical patent/WO2002045723A9/en
Anticipated expiration legal-status Critical
Publication of WO2002045723A3 publication Critical patent/WO2002045723A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Aggression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A process of decreasing the expression of one or more of the inflammatory cytokines IFN-y and IL-6 from cells in a mammalian patient, comprises administering to the patient an effective amount of stressed mammalian blood cells, said stressed cells having been extracorporeally subjected to at least one stressor selected from oxidative stress and ultraviolet radiation. These findings are indicative of the use of the process in the treatment for alleviation of chronic fatigue syndrome.
PCT/CA2001/001745 2000-12-05 2001-12-05 Inflammatory cytokine secretion inhibition with modified mammalian blood Ceased WO2002045723A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20010999376 EP1365842A2 (en) 2000-12-05 2001-12-05 Inflammatory cytokine secretion inhibition
CA002430937A CA2430937A1 (en) 2000-12-05 2001-12-05 Inflammatory cytokine secretion inhibition
AU2002215735A AU2002215735A1 (en) 2000-12-05 2001-12-05 Inflammatory cytokine secretion inhibition with modified mammalian blood

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002327631A CA2327631A1 (en) 2000-12-05 2000-12-05 Inflammatory cytokine secretion inhibition
CA2,327,631 2000-12-05

Publications (3)

Publication Number Publication Date
WO2002045723A2 WO2002045723A2 (en) 2002-06-13
WO2002045723A9 WO2002045723A9 (en) 2002-12-19
WO2002045723A3 true WO2002045723A3 (en) 2003-09-04

Family

ID=4167833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001745 Ceased WO2002045723A2 (en) 2000-12-05 2001-12-05 Inflammatory cytokine secretion inhibition with modified mammalian blood

Country Status (4)

Country Link
EP (1) EP1365842A2 (en)
AU (1) AU2002215735A1 (en)
CA (1) CA2327631A1 (en)
WO (1) WO2002045723A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138432A1 (en) * 2004-07-20 2008-06-12 Vasogen Ireland Limited Acute Inflammatory Condition Treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
WO2001052870A1 (en) * 2000-01-18 2001-07-26 Vasogen Ireland Limited Treatment of congestive heart failure by pretreated autologous blood
WO2001055348A1 (en) * 2000-01-28 2001-08-02 Vasogen Ireland Limited Improved inhibition of graft versus host disease
WO2001085185A2 (en) * 2000-05-11 2001-11-15 Vasogen Ireland Limited Treatment of il-10 deficiencies
WO2001089536A2 (en) * 2000-05-25 2001-11-29 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
WO2001052870A1 (en) * 2000-01-18 2001-07-26 Vasogen Ireland Limited Treatment of congestive heart failure by pretreated autologous blood
WO2001055348A1 (en) * 2000-01-28 2001-08-02 Vasogen Ireland Limited Improved inhibition of graft versus host disease
WO2001085185A2 (en) * 2000-05-11 2001-11-15 Vasogen Ireland Limited Treatment of il-10 deficiencies
WO2001089536A2 (en) * 2000-05-25 2001-11-29 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Also Published As

Publication number Publication date
AU2002215735A1 (en) 2002-06-18
WO2002045723A2 (en) 2002-06-13
WO2002045723A9 (en) 2002-12-19
CA2327631A1 (en) 2002-06-05
EP1365842A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
DK1071439T3 (en) Hip formulations as anti-inflammatory herbal medicine for the relief / reduction of symptoms associated with inflammation and arthritis
DE69905368D1 (en) Oxydiertes thymosin beta 4
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
BG100960A (en) DOSAGE FORMS WITH CONTROLLED RELEASE OF ASITROMYCIN
EP1944322A3 (en) Treatment of TNF alpha related disorders
WO2005107793A3 (en) Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2003073981A3 (en) Novel of cytokine inhibitors
DE602004018944D1 (en) USE OF SUPPLEMENT FOR TREATMENT OF IRRITATION SYNDROME
BR0213293A (en) Use of tfpi or tfpi analog in the treatment of septicemia
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
BR0107960A (en) Treatment of allergic and inflammatory conditions
WO2002045723A3 (en) Inflammatory cytokine secretion inhibition with modified mammalian blood
SE9902597D0 (en) New use
NZ515173A (en) Treatment of hypersensitivity reaction disorders
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
IL162268A0 (en) Tempamine compositions and methods of use
MXPA04000418A (en) Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines.
WO2002045724A3 (en) Use of modified mammalian blood for treating transforming growth factor related diseases
DK1150981T3 (en) Therapeutic necleoside compound
TW200513258A (en) Auxiliary agent for hepatitis C

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2430937

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001999376

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001999376

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001999376

Country of ref document: EP